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Anti-Fx1A produces complement-dependent cytotoxicity of glomerular
epithelial cells. Glomerular injury in passive Heymann nephritis (PHN)
in rats is mediated by the C5b-9 membrane attack complex (MAC) and
is associated with morphologic changes in glomerular visceral epithelial
cells (GEC). We determined if the nephritogenic antibody of PHN (yl
sheep anti-FxIA IgG) directs insertion of the MAC into GEC plasma
membranes with consequent cytotoxicity. Antibody-sensitized GEC
were exposed to various sera serving as sources of complement. Loss
of cell viability was determined by trypan blue uptake and/or by release
of cellular lactate dehydrogenase (LDH). Incubation of antibody-
sensitized primary and passaged GEC in fresh human serum (FHS)
resulted in sigmoidal relationships between cytotoxicity and comple-
ment dose (r = 0.97 and 0.94, respectively) such that cytolysis ap-
proached 100% with FHS (10% vol/vol). Cytotoxicity was not evident if
C8-deficient (C8D) plasma was substituted for FHS, but was restored in
a dose-dependent manner by reconstitution with purified rat C8.
Sublytic injury was demonstrated by wide separation between simulta-
neous release curves of cell-incorporated biscarboxyethyl carboxy-
fluorescein (BCECF; mol wt 520) and LDH at limiting doses of
complement (at 2% FHS, BCECF release was 51.1 0.6% of maximum
vs. 3.2 1.3% for LDH; N = 3) and by blebbing of the plasma
membrane on electron microscopy. Thus, the pathogenic antibody of
PHN produces complement-mediated sublytic as well as lytic cytotox-
icity of GEC.
Activation of the complement pathway near a cell surface
leads to the formation and insertion of the C5b-9 membrane
attack complex (MAC) into the plasma membrane. In nucleated
cells this may result in cytolysis or sublytic injury [1]. An
example of the pathophysiological consequences of such effects
is provided by the observation that glomerular injury in the
passive Heymann nephritis (PHN) model of experimental mem-
branous nephropathy in the rat is complement-mediated but is
leukocyte-independent [2, 3]. PHN is induced by a single
intravenous injection of heterologous antibody to rat proximal
tubular brush border (anti-Fx1A), whereupon a lesion morpho-
logically resembling human membranous nephropathy devel-
ops. PHN is characterized by subepithelial immune deposits
and marked proteinuria, and is the consequence of antibody
binding in situ to a resident glomerular antigen 14—61 that has
been shown to be a component of the glomerular visceral
epithelial cell (GEC) plasma membrane [7—9].
Several immunohistological studies have documented MAC
neoantigens in the glomerular lesions of rats with active and
passive Heymann nephritis [10—121 thus suggesting a possible
role for the membranolytic action of complement. Studies
showing that C6 is essential for the development of proteinuria
in both a rabbit model of membranous nephropathy induced
with cationized bovine albumin [131 and in PHN [141, demon-
strated the functional importance of the terminal complement
sequence in certain models of glomerular injury. In a cell-free,
plasma-perfused isolated rat kidney model of the autologous
phase of PHN, we recently found that proteinuria induced by
subepithelial immune complex formation in situ is dependent on
the presence of C8 [151. Similarly, development of proteinuria
in kidneys containing heterologous, complement-fixing anti-
FxlA occurred only in perfusions with complement-replete
plasma, but was absent when C6-deficient or C8-deficient (C8D)
plasmas were utilized [161. Because C8 is essential for comple-
ment-mediated membrane damage and has no other defined
role, it was reasonable to conclude that injury in rat membra-
nous nephropathy is mediated by the MAC. Moreover, ultra-
structural examination of kidneys perfused with C8-replete, but
not C8D plasma showed extensive podocyte damage, suggest-
ing that the GEC was the site of complement-induced injury
1151. Therefore, we proposed that altered glomerular permse-
lectivity in experimental membranous nephropathy follows the
insertion of the MAC into the GEC plasma membrane, leading
to GEC injury.
In this study, our aim was to substantiate the hypothesis that
the GEC can serve as a primary target for antibody-directed
complement-mediated injury. We therefore examined the abil-
ity of the nephritogenic antibody of PHN, anti-Fx1A, to induce
complement-mediated cytolysis of cultured GEC. Recognizing
that GEC lysis is not a feature of human or experimental
membranous nephropathy and that nucleated cells may be
subject to complement-induced injury without overt lysis [1,
171, we also sought evidence of sublytic cytotoxicity. Our
results show that anti-Fx1A binds directly to membrane anti-
gen(s) of cultured GEC, where it activates complement and
induces sublytic as well as lytic injury.
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Antibody and complement components
The complement-fixing, nephritogenic 71 subclass of sheep
anti-FxlA and nonimmune yl sheep IgG were prepared and
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characterized as described previously [2—41. A pool of freshly
frozen, normal human serum (FHS) was used as a stock source
of C1-C9. The same serum, heat-inactivated at 56°C for 30
minutes, served as a negative control. C8D human plasma was
obtained by plasmapheresis from a patient congenitally lacking
the /3 subunit of C8 [18]. A pool of freshly frozen serum from
adult Sprague-Dawley rats was used as a stock source of rat
complement and to purify C8. Rat serum was treated with
protease inhibitors and C8 was isolated by sequential precipi-
tation with 15% (wt/vol) polyethylene glycol 4000 (Fisher Sci-
entific Co., Fair Lawn, New Jersey, USA) and column chro-
matography on DEAE-Sephacel, Sephacryl S-200 (Pharmacia
Fine Chemicals, Uppsala, Sweden), and CM 52-cellulose
(Whatman Inc., Clifton, New Jersey, USA) as described for
human complement components by Hammer et at [191. C8
activity was monitored through each isolation step using a
microtiter C8 hemolytic assay that utilizes sheep erythrocytes
coated with antibody and guinea pig Cl, human C4-7, and
guinea pig C9 (Cordis Laboratories, Miami, Florida, USA).
Hemolytic activity of the final preparation was assayed by a test
tube method as previously described [15] and its protein con-
centration was determined by the Lowry method [20]. Rat C8
was purified approximately 1250-fold (2.3 X 106 C8 U/mg
protein) as compared to rat serum and was virtually devoid of
C6 activity (480 C6 U/mg protein), thus excluding significant
contamination with the complement component most likely to
copurify with C8 [191.
Culture of rat glomerular epithelial cells
Passaged rat GEC (provided by D. A. Ausiello, Massachu-
setts General Hospital, Boston, Massachusetts, USA) were
used for experiments on cells in suspension. These cells were
cultured as described [211, using RPMI-l640 medium (Grand
Island Biological Co., GIBCO, Grand Island, New York, USA)
supplemented with 10% fetal calf serum. For passage, confluent
GEC were suspended by incubating with a 0.05% trypsin-0.02%
EDTA mixture in Ca- and Mg-free Hank's balanced salt
solution (HBSS; GIBCO). Dissociated cells were resuspended
in culture medium and plated onto 100 mm tissue culture dishes
(Falcon Plastics, Oxnard, California, USA) at 5 x l0 cells/l00
mm dish. Cytotoxicity studies were performed three to five
days after plating, at which time cells were close to, or had
reached confluency. Cells were studied between the 18th and
23rd passages. All cultures were maintained at 37°C in an
atmosphere of 95% air and 5% CO2.
Primary cultures of GEC were established as described [21,
22] with minor modifications. Renal cortical tissue was obtained
from 250 g male Sprague-Dawley rats (CDR, Charles River
Breeding Laboratories, Wilmington, Massachusetts, USA).
Glomeruli were isolated by sieving with, successively, 170-,
80-, and 200-mesh stainless steel screens (W.S. Tyler, Inc.,
Mentor, Ohio, USA). The glomerular preparation was collected
on the 200-mesh screen and consisted of 90 to 95% decapsulated
glomeruli and fewer than 5% tubules. Glomeruli were slis-
pended in Kl-3T3 medium [22] and plated in 6-welt cluster
dishes (Falcon Plastics) containing 12 x 12 mm glass cover slips
(Bradford Scientific, Epping, New Hampshire, USA). Almost
all cells that grew out of glomeruli after four to nine days had
the appearance of GEC [23] and were identified as such, as
described below. Experiments were performed on the nearly
confluent monolayers after seven to nine days.
For morphological studies, GEC were cultured on a collagen
matrix (Vitrogen 100, Collagen Corp., Palo Alto, California,
USA). Glomeruli in Kl-3T3 medium were plated onto collagen-
coated culture dishes [prepared as described in 22]. Following
seven to nine days in culture, areas of confluent GEC were
localized by phase-contrast microscopy and isolated by cutting
around the desired area with a scalpel blade. The cells and
adherent matrix were removed with a pasteur pipet and replated
into one well of a 24-well cluster dish coated with collagen. In
general, glomeruli and any early-appearing mesangial cells
could be excluded by this technique, thus allowing for the
selection of homogeneous populations of GEC. Confluent cells
were passaged by removing the collagen matrix and adherent
cells with sterile forceps, placing this into a tube containing 4 ml
of 0.2% collagenase (CLS IV, Cooper Biomedical, Malvern,
Pennsylvania, USA) in HBSS, and incubating for 30 to 60
minutes at 37°C until the visible collagen had dissolved. Cells
were pelleted by centrifugation at 200 x g for three minutes,
washed once with Ca - and Mg k-free HBSS, and then
incubated with I ml of a 0.05% trypsin-0.02% EDTA mixture inCa - and Mg -free HBSS for 10 minutes at 37°C. Clumps of
cells were dissociated by aspirating up and down with a pasteur
pipet, trypsin activity was neutralized with excess medium, the
cells were pelleted, and then resuspended in the desired amount
of Kl-3T3 medium and passaged onto collagen-coated dishes.
After the eighth passage 3T3 conditioned medium was no longer
needed with the K! medium. Studies were performed on cells
between the 8th and 23rd passage.
Primary and passaged cells were identified as GEC by stan-
dard criteria [24, 251. By phase-contrast microscopy, subconflu-
ent passaged GEC were polygonal in shape. They assumed a
characteristic cobblestone-like appearance upon reaching
confluency [24]. Until the ninth day in primary culture, greater
than 95% of the cells that grew from glomeruli also had these
morphologic features. After addition of low doses (25 to 100
g/ml) of the aminonucleoside of puromycin (Sigma Chemical
Co., St. Louis, Missouri, USA) to the medium, spindling and
rounding of the cells occurred and at the higher doses many
cells detached from the culture dish within 24 hours [261.
Subconfluent cells, grown on glass coverslips, fixed at —20°C
with methanol, and stained with guinea pig anti-bovine hoof
keratin (Miles Laboratories, Naperville, Illinois, USA) and
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-guinea
pig IgG (Cappel Laboratories, West Chester, Pennsylvania,
USA) exhibited fibrillar cytoplasmic staining with perinuclear
accentuation typical of epithelial cells [25, 27]. This staining
pattern was not seen when normal guinea pig serum was
substituted for the primary antibody.
Measurements
Loss of cell viability was assessed by the release of lactate
dehydrogenase (LDH) and/or by inclusion of the vital dye,
trypan blue. Release of cell-incorporated low molecular weight
markers, biscarboxyethyl carboxyfluorescein (BCECF, mol wt
520; Molecular Probes, Eugene, Oregon, USA) or
aminoisobutyric acid (14C-AIB; mol wt = 103; New England
Nuclear, Boston, Massachusetts, USA) was used to evaluate
sublytic cytotoxicity. After incubation for 5 to 10 minutes with
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0.2% trypan blue, the number of cells that stained positively
with the vital dye was determined by counting 100 cells with
bright-field microscopy. Percent specific trypan blue uptake
was calculated from the formula (E — C)/(l00 — C) X 100,
where E is experimental trypan blue uptake and C is uptake by
control cells.
LDH activity was determined from the rate of reduced
nicotinaniide adenine dinucleotide (NADH) generation during
the LDH-catalyzed conversion of lactate to pyruvate in the
presence of NAD. A 100 d aliquot of each cell supernatant and
200 Mi of 0.1 M lactate (pH 7.0, Sigma) were added to 2.0 ml of
a solution containing 80 m Tris (Sigma), 700 mrvi hydrazine
(Eastman Kodak Co., Rochester, New York, USA), 2 mM
EDTA (Sigma), and 2 mrvi NAD (Sigma) at pH 9.0. NADH
generation was measured in a double-beam spectrophotometer
(Perkin-Elmer Co., Norwalk, Connecticut, USA) by the rate of
increase in absorption at 340 nm over time. This value repre-
sents LDH activity. Specific LDH release is expressed as a
percentage of the maximum amount of LDH activity released
from the same cells lysed by melittin (50g/ml, Sigma), and was
calculated from the equation (E — S)/(M — 5) X 100, where E
is experimental release, S is spontaneous release, and M is
maximum release (E plus melittin-induced release).
BCECF-acetoxymethyl ester freely enters live cells where it
is de-esterified to BCECF, a negatively charged molecule that is
retained by normal cells [28]. GEC were loaded by incubating 2
x 106 cells/mi for 30 minutes at 22°C in 8 tM BCECF-acetoxy-
methyl ester (0.8 m in dimethyl sulfoxide) diluted in gelatin-
veronal buffer (GVB; vjde infra). BCECF released into the
supernatant was quantitated spectrofluorimetricaily (Perkin-
Elmer Co.) using an excitation wavelength of 506 nm and an
emission wavelength of 530 nm. Aliquots of 100 d, containing
1 x 106 BCECF-loaded cells/mi, produced an adequate signal to
detect spontaneous release. Spontaneous release of BCECF
after a 30 minute incubation at 37°C was 4.2 0.2% (N = 3) of
the maximum releasable BCECF; trypan blue uptake of loaded
cells in buffer alone was 4.3 0.9% (N = 3). Specific BCECF
release was calculated as described for LDH.
14C-AIB (52.6 mCi/mmol), a cell-incorporated, non-utilized
amino acid, was used as described by Ramm et al [29] with
minor modifications. GEC were loaded by incubating I x 106
cells/mi in RPMI buffer (RPMI 1640 with 25 mM Hepes and 2%
bovine serum albumin, pH 7.4) with 10 pCi/mI '4C-AIB for 60
minutes at 37°C. Extracellular 4C-AIB was removed as de-
scribed [29]. Cytotoxicity studies with '4C-AIB were done at
30°C because of a high spontaneous leak rate at 37°C as
previously noted [29]. Preliminary cytotoxicity kinetics showed
that maximum '4C-AIB release occurred within 15 minutes and,
as this time period was associated with a moderately low
spontaneous leak rate (mean SEM = 16.4 5.8%, N = 3), it
was chosen for these experiments. Release of 4C-AIB was
measured in aliquots of supernatant added to scintillation
cocktail (Formula 963, New England Nuclear) and counted in a
/3-scintillation counter (Beckman Instruments, Inc., Fullerton,
California, USA). Total releasable '4C-AIB was measured by
adding cells directly to scintillation fluid; this gave identical
results to counting the lysate of cells treated with melittin.
Specific '4C-AIB release was calculated as described for LDH.
Studies on GEC in suspension
GEC were brought into single-cell suspension by washing
confluent monolayers twice with Ca- and Mg-free HBSS,
following which a 0.05% trypsin-0.02% EDTA solution in
Ca- and Mg-free HBSS was added to the culture dish and
immediately poured off. The cells were subsequently incubated
in 10 ml of Ca- and Mg-free HBSS for five minutes at 37°C.
Two ml of soybean trypsin inhibitor (Sigma) at 1 mg/ml in
HBSS was then added to the suspended cells and the suspen-
sion centrifuged at 200 x g for three minutes. The cell pellet was
resuspended in veronal buffered saline (145 mrvi NaC1, 5 mM Na
barbital, pH 7.4), washed twice, and adjusted to a concentration
of 1 x 106 cells/mI in GVB (veronal buffered saline containing
0.1% gelatin, 0.15 mrvi CaCl2, and 1 mrvi MgC12).
Sensitization of GEC with anti-FxIA. To determine the
optimal sensitizing dose of anti-FxlA, GEC at 1 x l06/ml in
GVB were incubated for 30 minutes at 22°C with 0.25 to 8 mg/mI
of yl anti-FxIA. Sensitization with antibody was done at 22°C
to limit the redistribution of antigen [9]. Following two washes
with GVB, the cells were resuspended in GVB and aliquoted
into individual wells of a microtiter plate containing FHS so that
each well contained 2 x i05 cells in 200 sl with 10% FHS as a
source of excess complement. Incubation was performed for 90
minutes at 37°C to ensure that end-point lysis was reached [I],
although subsequent time-course studies showed that complete
marker release or uptake occurred within 30 minutes. After
incubation, the cells were centrifuged at 200 x g for three
minutes. The cell pellet was resuspended in 50 d veronal
buffered saline for trypan blue staining. The supernatant was
centrifuged at 2500 x g for five minutes to remove any cellular
debris and 3tored at —70°C for LDH analysis. Controls included
an experiment in which nonimmune yl sheep IgG was substi-
tuted for anti-FxlA and another in which sensitized cells were
exposed to 10% heat-inactivated serum instead of FHS. To
determine maximum release of cellular LDH in these initial
studies, 2 x l0 cells were incubated in parallel for 30 minutes
at 22°C in 200 tl GVB containing 50 sg/ml melittin.
Complement-mediated cytolysis. a) GEC were sensitized
with the optimum dose of 4 mg/mI of anti-FxIA, as described
above. Aliquots of 2 x l0 cells were then incubated in triplicate
at 37°C for 45 minutes with various concentrations of FHS (0 to
10% vol/vol) in 200 d GVB. After incubation, viability was
determined by LDH release. b) The role of C8 in mediating
GEC cytolysis was assessed by exposing antibody-sensitized
cells to C8D plasma alone or to C8D plasma reconstituted with
rat C8. GEC were sensitized and incubated in triplicate, as
described above, with 10% C8D plasma and increasing concen-
trations of rat C8 (0 to 11.7 ig/ml). Sensitized cells were also
exposed to C8 (1.46 g/ml) in the absence of C8D plasma. After
incubation at 37°C for 45 minutes, cells and supernatant were
processed for trypan blue uptake and LDH release.
Complement-mediated sublytic cytotoxicity. Sublytic injury
of sensitized GEC was assessed at limiting doses of total
complement and C8 by the release of small intracellular mark-
ers. Cell viability was monitored by vital dye exclusion and
LDH release, a) GEC were loaded with BCECF, sensitized
with 4 mg/mI yl anti-FxlA and then incubated in triplicate with
various concentrations of FHS (0 to 2%) at 37°C. Specific
release of BCECF was measured after 30 minutes and cell
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viability was assessed by specific release of LDH after 30
minutes and 180 minutes. Antibody-independent complement-
mediated BCECF release was measured in similar fashion using
unsensitized cells. b) Cells loaded with '4C-AIB and sensitized
with 4 mg/mI yl anti-Fx 1 A were incubated in triplicate at 30°C
with an excess of C8D plasma (10%) and increasing concentra-
tions of rat C8 (0 to 3 tg/ml). After 15 minutes, cells were
examined for trypan blue uptake and specific release of '4C-AIB
was measured.
Studies on primary explants
Coverslips containing primary monolayer outgrowths of GEC
from glomeruli were washed with GVB and then sensitized with
antibody by adding 2 ml of GVB containing anti-Fx1A (30
minutes at 22°C). Cells were then washed with GVB and
incubated with various amounts of FHS or 10% C8D plasma
reconstituted with incremental concentrations of C8, for 45
minutes at 37°C. Experiments were also performed utilizing
fresh normal rat serum in place of human serum to determine if
cytotoxicity of GEC also occurs with homologous complement
components. Controls included unsensitized cells (preincu-
bated without antibody) and sensitized cells exposed to heat-
inactivated serum or C8D plasma (without added C8) instead of
FHS. The cells were then washed with ice-cold GVB, the cover
slips removed, placed on microscope slides, and incubated for
five minutes with trypan blue. Each field was then viewed by
light microscopy and the percentage of cells stained with trypan
blue was assessed. Only cells that exhibited the typical mor-
phology of GEC and were clearly associated with a glomerulus
were counted.
Morphological studies
Cell morphology was correlated with functional evidence of
sublytic and lytic injury, as follows: Confluent GEC in collagen-
coated 24-well cluster dishes were loaded with BCECF (4 LM
BCECF-acetoxymethyl ester in 1 ml GVB per well) and were
then exposed to anti-FxlA in GVB for 30 minutes at 22°C. After
washing, cells were exposed to varying amounts of fresh rat
serum in GVB for 45 minutes at 37°C and were then fixed with
2% glutaraldehyde (Ladd Research Industries, Inc., Burlington,
Vermont, USA) in 0.1 M phosphate buffer, pH 7.2, for a
minimum of one hour at 4°C. Controls included sensitized cells
exposed to heat-inactivated serum or to buffer alone. In parallel
groups of identically treated cells, cytotoxicity was measured
by BCECF and LDH release as described above. The fixed
monolayers on collagen were removed, one third cut into thin
strips, and processed for transmission electron microscopy
according to previously described methods [301. At least 20
cells were examined from each experimental and control group.
The remainder of each monolayer was processed, dried,
mounted, and sputter coated with 200 A of gold as previously
described [301, and examined in a JEOL 35U scanning electron
microscope at 20 kV.
Statistics
All incubations were done in triplicate and the results are
expressed throughout as the mean SEM unless otherwise
indicated. Dose-response curves were linearized according to
formulas that describe a sigmoidal curve 1311 or that utilize
Poisson theory [32] and were then subjected to regression
analysis.
Results
Cytotoxicity as a function of antibody concentration
In the presence of excess complement (10% FHS), GEC
lysis, measured by trypan blue uptake and by LDH release, was
related to the concentration of anti-Fx1A (Fig. 1). Maximum
LDH release (88.2 6.8%) and trypan blue uptake (81.1
2.0%) were reached at an anti-FxIA IgG concentration of 4.0
mg/mi. These measurements were regarded as analogous in
further experiments utilizing a sensitizing dose of 4.0 mg/ml of
anti-Fx1A IgG. In control experiments, unsensitized GEC
incubated in buffer followed by 10% FHS demonstrated 8.3
1.4% trypan blue uptake, while GEC incubated with non-
immune sheep IgG (0.5 and 2.0 mg/mi) followed by 10% FHS
demonstrated 15.7 3.2% and 10.3 1.8% trypan blue uptake,
respectively. When GEC were incubated with anti-FxlA IgG
(0.5 to 5.0 mg/mI) and 10% heat-inactivated serum, trypan blue
uptake and LDH release were the same as in GEC incubated
with heat-inactivated serum alone.
Antibody-directed complement-mediated cytolysis
GEC sensitized with anti-Fx1A were exposed to various
concentrations of FHS. As demonstrated in Figure 2, there was
a sigmoidal dose-response relationship between FHS concen-
tration and LDH release (r = 0.94). Whereas no injury was
observed when sensitized cells were exposed to 10% C8D
plasma (vol/vol), cytotoxicity was restored in a dose-dependent
fashion by reconstituting 10% C8D plasma with increasing
concentrations of rat C8 (Fig. 3). C8, when added alone to
antibody-sensitized cells resulted in only 1.7 0.3% trypan
blue uptake and 3.4 3.4% LDH release, while at the same
dose (1.46 sg/ml) in the presence of 10% C8D plasma, trypan
blue uptake was 44.7 1.9% and LDH release was 37.9 6.7%
(Fig. 3). In a separate experiment, trypan blue uptake reached
88.1 2.1% and LDH release reached 92.9 21.3% when 10%
C8D plasma was fully reconstituted with rat C8 (11.7 pg/ml).
Sublytic effects of complement
The ability of low concentrations of complement to perturb
cell membrane integrity without producing overt lysis was
demonstrated by the release of two small markers previously
incorporated into the cells. Figure 4 depicts the release of the
fluorescent probe BCECF from sensitized GEC exposed to
FHS (0 to 2%) at 37°C for 30 minutes. A sigmoidal dose-
response was found (r 0.99) in which 2% FHS released 51.1
0.6% of releasable BCECF. In contrast, LDH release was
lower at all concentrations of FHS and reached only 3.2 1.3%
of maximum releasable LDH in the presence of 2% FHS for 30
minutes. LDH release after 180 minutes of incubation was
identical to that at 30 minutes, thus establishing the viability of
most cells and ensuring that the low levels of LDH were not
simply due to delayed release. In separate experiments,
BCECF release in the presence of 2% FHS was 1.3 0.6% with
unsensitized cells and 41.6 3.2% with antibody-sensitized
cells.
Sublytic injury was also demonstrated by release of the small,
cell-incorporated marker, 14C-AIB, on exposure of sensitized
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Fig. I. Cytolysis of passaged GEC as a function of anti-FxIA concen-
tration. GEC in suspension were incubated with various concentrations
of anti-Fx1A for 30 mm at 22°C, washed, and subsequently exposed to
10% FHS (vol/vol) as a source of excess complement for 90 mm at 37°C.
Specific LDH release, as a percentage of maximum releasable (•), was
measured in the supernatant and trypan blue uptake was determined on
the cells (•). In unsensitized cells exposed to 10% FHS there was no
detectable LDH release and trypan blue uptake was 6.7 0.9%. These
values were used to calculate specific LDH release and trypan blue
uptake.
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Fig. 3. Effect of C8D plasma alone or after reconstitution with C8 on
cytolysis of passaged GEC. Antibody-sensitized GEC (Fig. 2 legend) in
suspension were incubated for 45 mm at 37°C with C8D plasma (10%
vol/vol) to which various concentrations of purified rat C8 were added.
In one group of cells, C8D plasma was omitted to determine the effect
of C8 alone. LDH release was measured on the supernatant as a
percentage of maximum releasable LDH (LI), and trypan blue uptake
was determined on the cells (a).
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Fig. 2. Cytolysis of passaged GEC as afunction of FHS concentration.
GEC were sensitized with anti-FxIA (4 mg/mI) and incubated in
suspension with various concentrations of FHS (•) for 45 mm at 37°C
and LDH release determined. Specific LDH release was calculated by
subtracting the uptake by antibody-sensitized cells exposed to buffer
alone (2.3 1.4%).
GEC to an excess of C8D plasma and limiting doses of rat C8
(Fig. 5). Because AIB is sufficiently small to pass through
individual complement lesions, the curve relating AIB release
to C8 concentration passes through the origin and resembles
curves that describe a "single-hit" phenomenon (r =
—0.95) [1,
32]. Furthermore, the absence of trypan blue uptake at lower
doses of C8 (<1.5 tg/ml) indicates that altered membrane
permeability to AIB occurred in otherwise viable cells (Fig. 5).
The values of trypan blue uptake in Figure 5 differ from those in
Figure 3 because AIB-loaded cells were incubated in FHS at
30°C to avoid an unacceptably high spontaneous leak rate
observed at 37°C.
Fig. 4. Sublytic cytotoxicity of passaged GEC. BCECF was released in
the absence of LDH release at limiting concentrations of FHS. GEC in
suspension were loaded with BCECF, sensitized with antibody (Fig. 2
legend), and then exposed to various concentrations of FHS for 30 mm
at 37°C. Specific release of LDH (•) and BCECF (Lfl into the medium
was determined and expressed as a percentage of maximum releasable
marker from the same cells. With antibody-sensitized, BCECF-loaded
cells exposed to buffer alone, LDH release was 0.3 0.2% of maximum
releasable and BCECF release was 4.2 0.2% of maximum releasable.
These values were subtracted to calculate specific release.
Studies on primary explants
Under conditions of excess complement (10% FHS), a lower
concentration of anti-FxlA (0.5 mg/mI) was required to sensi-
tize cells and achieve maximal cytotoxicity. A sigmoidal cyto-
toxicity curve (r = 0.99) of trypan blue uptake was obtained
using explanted GEC from two separate isolations after sensi-
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Fig. 6. Effects of heterologous and homologous complement on viability
of primary cultures of GEC. Trypan blue uptake was greater with FHS
than with rat serum. Primary explants of GEC on cover slips were
incubated with anti-Fx1A (0.5 mg/mI), washed, and subsequently
exposed to various concentrations of FHS (•) or fresh normal rat
serum (0) for 45 mm at 37°C. Trypan blue uptake was then determined
on the GEC. At each FHS concentration, 300 cells were counted from
at least 3 separate fields; experiments were done on 2 separate explants
and the data is expressed as the average of these. At each concentration
of rat serum, 3 separate cover slips were used from the same explant;
data is expressed as the mean SEM. Specific trypan blue uptake was
calculated by subtracting the uptake by antibody-sensitized GEC ex-
posed to buffer alone (8.5% in the FHS experiments and 17.7 11.0 in
the rat serum experiments).
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Fig. 7. Cytotoxicity of primary cultures of GEC as a function of C8
concentration. Antibody-sensitized primary explants of GEC (Fig. 6
legend) on cover slips were incubated for 45 mm at 37°C with C8D
plasma (10% vol/vol) reconsituted with various concentrations of rat
C8, Trypan blue uptake was determined on 300 cells from at least 3
separate fields at each C8 concentration. The data are expressed as the
specific percentage of cells staining with trypan blue and was calculated
by subtracting the uptake by antibody-sensitized GEC exposed to 10%
C8D plasma alone (6.4%).
The addition of complement (fresh rat serum) to antibody-
sensitized cells resulted in the formation of vesicular structures
both on the cell surface and in intercellular junctions (Figs. 8B
and 9B). Intercellular vesicular structures were present in 1 of
C8 concentration, pg/mI
Fig. 5. Sub! ytic cytotoxiciry of passaged GEC. 14C-AIB was released in
the absence of trypan blue uptake at concentrations of C8 < 1 .5 g/ml.
GEC in suspension were loaded with '4C-AIB, sensitized with antibody
(Fig. 2 legend), and subsequently incubated for 15 mm at 30°C with C8D
plasma (10% vol/vol) to which various concentrations of purified rat C8
were added. 4C-AIB release into the supernatant was determined and
expressed as a percentage of total cellular '4C-A1B (0). Cellular uptake
of trypan blue was also measured (•). '4C-AIB release from antibody-
sensitized cells exposed to 10% C8D plasma alone was 10.0 0.4%
while trypan blue uptake on these cells was 6.0 0.0%. These values
were subtracted to determine specific AIB release and trypan blue
uptake.
tization with antibody and exposure to incremental concentra-
tions of human complement (Fig. 6). Figure 6 also shows the
sigmoidal, cytolytic dose-response curve (r = 0.97) of sensi-
tized primary explants of GEC exposed to fresh rat serum as a
source of homologous complement. At any given concentration
of serum, cytotoxicity was greater with human than rat serum,
reaching 50% with 3.5% FHS and 15% rat serum. Trypan blue
uptake on antibody-sensitized GEC exposed to 10% heat-
inactivated serum was 7.8%, while on unsensitized cells ex-
posed to 10% FHS, trypan blue uptake was 14.2% (average of
2 separate explants). Using the same technique, cytoxicity of
antibody-sensitized primary explants of GEC was also demon-
strated with 10% C8D plasma reconstituted with 0 to 4 tg/ml of
rat C8 (Fig. 7).
Morphological studies
Morphological changes associated with sublytic and lytic
injury were evaluated in monolayer cultures of GEC on a
collagen matrix. Release of BCECF and LDH from GEC
exposed to antibody and complement was measured and com-
pared to the morphology of a parallel group of cells. As in GEC
in suspension (Fig. 4), curves relating BCECF and LDH release
to serum concentration were sigmoidal, with BCECF release
being greater than LDH release at all serum doses (data not
shown). GEC exposed to anti-FxlA and subsequently to buffer
alone or to excess heat-inactivated serum did not show in-
creased BCECF or LDH release above background, and they
exhibited normal morphology characteristic of epithelial cells,
including apical microvilli, desmosomes, and tight junctions.
(Figs. 8A and 9A).
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Fig. 8. Transmission electron microscopy of antibody-sensitized GEC exposed to complement. A. GEC exposed o 25% heat-inactivated rat serum.
Cells appear normal with apical microvilli (arrowhead), tight junctions (long straight arrow), and desmosomes (avy arrows). B. GEC exposed to
7.5% normal rat serum. Microvilli (arrowheads) and tight junctions (long straight arrow) are present as in controls, however desmosomes are
absent. In addition, numerous vesicular structures are seen both on the apical surface and in between cells (short arrows). A few strands of striated
collagen present in the lower portion of the micrograph are from the matrix on which the cells were cultured. (X 10,700)
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Fig. 9. Scanning electron microscopy of antibody-sensitized GEC exposed to complement. A. GEC exposed to 25% heat-inactivated rat serum.
Cells appear normal with microvilli, elevated central regions, and depressed cell borders. B. GEC exposed to 5.0% normal rat serum. Cells are
irregularly shaped and have numerous vesicular structures on their surfaces (arrows). C. GEC exposed to 20% normal rat serum. A cell has a large
defect in the plasma membrane and numerous surface blebs are present. The scale bars represent 10 m.
10 cellular junctions of antibody-sensitized cells exposed to
buffer alone, while 6 of 10 junctions in antibody-sensitized cells
exposed to 5.0% serum were widened and contained vesicles.
In addition, well-developed desmosomes that were present in
normal cells were lost in cells exposed to complement (compare
Fig. 8A and Fig. 8B). Normal desmosomes were visible in 8 of
20 antibody-sensitized cells exposed to buffer, while only 1 of
20 cells exposed to anti-FxlA and 7.5% serum had an identifi-
able, but abnormal, desmosome. This desmosome lacked the
electron-dense band normally seen between cells examined at
high power, and the intercellular space was widened. It is likely
that these changes are due to sublytic effects of complement as
LDH release was less than 4% in these cells, whereas BCECF
release was 8.1 1.7% for cells exposed to 5.0% serum (Fig.
9B) and 22.8% (N = 2) in cells exposed to 7.5% serum (Fig. 8B).
When the serum concentration was raised, overt lysis became
increasingly apparent. This appeared as disruption of the
plasma membrane (Fig. 9C; 20% serum), cellular swelling, and
release of cytoplasmic contents.
Discussion
The results of this study are consistent with our hypothesis
that GEC are the primary target of injury in PHN [15], and
suggest that the nephritogenic antibody, anti-FxlA, might pro-
duce its in vivo effect by altering GEC structure or function.
Using antibody-sensitized GEC from either long-term or pri-
mary culture, cytotoxicity occurred only with complement-
replete heterologous or homologous serum and not with heat-
inactivated serum or C8D plasma. Complement caused little or
no antibody-independent cytotoxicity and antibody-directed
injury was entirely complement-mediated. Furthermore, when
C8D plasma was reconstituted with purified C8, cytotoxicity of
antibody-sensitized GEC was restored in a dose-dependent
manner. Because C8 is the key membranolytic component of
the CSb-9 complex and has no other known role [33], these
results demonstrate that GEC cytotoxicity is antibody-mediat-
ed and MAC-dependent.
By preloading GEC with low molecular weight markers
capable of traversing complement lesions in the plasma mem-
brane, it was possible to demonstrate loss of membrane integ-
rity in the absence of cytolysis, at limiting doses of comple-
ment. As illustrated in Figure 4, the fluorescent probe BCECF
(mol wt 520) was released at concentrations of complement
that failed to disrupt cells and discharge LDH (mol wt
140,000), a molecule too large to pass through the largest
complement channels [I]. Similarly, '4C-AIB (mol wt = 103)
was released at doses of C8 that did not affect vital dye
exclusion. It is noteworthy that the concave shape of the curve
of AIB release in response to limiting doses of C8 (Fig. 5),
concurs with previous observations in nucleated cells [34] and
provides functional evidence that a single MAC lesion is
required for the release of this molecule. The simultaneously
obtained lytic curve, however, is sigmoidal, implying that
multiple MAC lesions are necessary to cause loss of cell
viability [1]. Thus, substantial membrane perturbation can
occur in the absence of overt cytolysis, which is pertinent to an
understanding of the role of complement in PHN.
Cytotoxicity was evaluated in GEC from both primary and
passaged cultures to avoid potential artifacts from dedifferenti-
ation in long-term culture. The results are qualitatively similar,
although adherent primary cultures of GEC are more sensitive
than passaged GEC in suspension to anti-Fx1A, in that an
eightfold lower concentration of antibody was required for
maximal complement-dependent cytolysis of the explanted
cells. The reason for this finding has not yet been defined.
Nevertheless, long-term cultures of GEC are suitable for study-
ing the cellular events resulting from anti-FxlA binding and
complement activation, and have the distinct advantages of
being homogeneous and available in large numbers for quanti-
tative studies.
This study on cultured GEC and our recent experiments in an
isolated perfused kidney model [15] show that complement can
induce GEC lysis, under specific experimental conditions,
although histologic evidence of cell necrosis is not a frequent
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further delineation of potential MAC-induced intracellular pro-
cesses that might contribute to the permeability defect in PHN.
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